Comment on ‘Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity’ by Dupuis et al.

Documenti analoghi

• Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity
  di: Joséphine Dupuis, et al.
  Pubblicazione: (2024)
• Reply to ‘Real‐world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis’
  di: Fabrizio Martora, et al.
  Pubblicazione: (2025)
• Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate‐to‐severe atopic dermatitis: A nationwide retrospective cohort study
  di: Gianluca Avallone, et al.
  Pubblicazione: (2024)
• Detecting T‐cell receptor clonality in patients with severe atopic dermatitis refractory to dupilumab
  di: Hyungdon Kook, et al.
  Pubblicazione: (2024)
• Five‐year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real‐world study
  di: Luigi Gargiulo, et al.
  Pubblicazione: (2025)